NCT00193245View on ClinicalTrials.gov

Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 30, 2000

Primary Completion Date

October 31, 2005

Study Completion Date

January 31, 2009

Conditions
Lung Cancer
Interventions
DRUG

Topotecan

DRUG

Docetaxel

Trial Locations (1)

37023

Tennessee Oncology, PLLC, Nashville

Sponsors
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Aventis Pharmaceuticals

INDUSTRY

collaborator

GlaxoSmithKline

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER